132 related articles for article (PubMed ID: 21628416)
1. Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD.
Clark WB; Brown-Gentry KD; Crawford DC; Fan KH; Snavely J; Chen H; Savani BN; Kassim A; Greer JP; Schuening FG; Engelhardt BG; Jagasia MH
Blood; 2011 Jul; 118(4):1140-4. PubMed ID: 21628416
[TBL] [Abstract][Full Text] [Related]
2. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.
Jacobson CA; Sun L; Kim HT; McDonough SM; Reynolds CG; Schowalter M; Koreth J; Cutler CS; Ho VT; Alyea EP; Armand P; Blazar BR; Soiffer RJ; Antin JH; Ritz J; Sarantopoulos S
Biol Blood Marrow Transplant; 2014 May; 20(5):668-75. PubMed ID: 24462743
[TBL] [Abstract][Full Text] [Related]
3. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
4. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
5. Genetic risk factors for sclerotic graft-versus-host disease.
Inamoto Y; Martin PJ; Flowers ME; Lee SJ; Carpenter PA; Warren EH; Geraghty DE; Lee N; Boeckh MJ; Storer BE; Levine DM; Fan W; Zhao LP; Hansen JA
Blood; 2016 Sep; 128(11):1516-24. PubMed ID: 27313329
[TBL] [Abstract][Full Text] [Related]
6. BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation.
Jia W; Poe JC; Su H; Anand S; Matsushima GK; Rathmell JC; Maillard I; Radojcic V; Imai K; Reyes NJ; Cardona DM; Li Z; Suthers AN; Curry-Chisolm IM; DiCioccio RA; Saban DR; Chen BJ; Chao NJ; Sarantopoulos S
Blood; 2021 May; 137(18):2544-2557. PubMed ID: 33534893
[TBL] [Abstract][Full Text] [Related]
7. Genetic variations of interleukin-23R (1143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation.
Wermke M; Maiwald S; Schmelz R; Thiede C; Schetelig J; Ehninger G; Bornhäuser M; Wassmuth R
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1718-27. PubMed ID: 20541026
[TBL] [Abstract][Full Text] [Related]
8. NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.
Jaskula E; Lange A; Kyrcz-Krzemien S; Markiewicz M; Dzierzak-Mietla M; Jedrzejczak WW; Czajka P; Mordak-Domagala M; Lange J; Gronkowska A; Nowak J; Warzocha K; Hellmann A; Kowalczyk J; Drabko K; Gozdzik J; Mizia S;
Biol Blood Marrow Transplant; 2014 Mar; 20(3):409-14. PubMed ID: 24345423
[TBL] [Abstract][Full Text] [Related]
9. Discrepancy between recipient and donor rs4364254 heparanase single nucleotide polymorphism impacts graft-versus-host disease after allogeneic stem cell transplant.
Metafuni E; Giammarco S; Bellesi S; Rossi M; Minnella G; Limongiello MA; Valentini CG; Teofili L; Sica S; Chiusolo P
Int J Lab Hematol; 2023 Dec; 45(6):935-944. PubMed ID: 37646104
[TBL] [Abstract][Full Text] [Related]
10. Donor Genotype in the Interleukin-7 Receptor α-Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
Kielsen K; Enevold C; Heilmann C; Sengeløv H; Pedersen AE; Ryder LP; Müller K
Front Immunol; 2018; 9():109. PubMed ID: 29456530
[TBL] [Abstract][Full Text] [Related]
11. High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation.
Cho BS; Min CK; Kim HJ; Lee S; Kim YJ; Lim JY; Jeong DC; Cho B; Kim HK; Eom KS; Cho SG; Kim DW; Lee JW; Min WS; Kim CC; Chung NG
Biol Blood Marrow Transplant; 2010 May; 16(5):629-38. PubMed ID: 19963070
[TBL] [Abstract][Full Text] [Related]
12. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia.
Robien K; Bigler J; Yasui Y; Potter JD; Martin P; Storb R; Ulrich CM
Biol Blood Marrow Transplant; 2006 Sep; 12(9):973-80. PubMed ID: 16920564
[TBL] [Abstract][Full Text] [Related]
13. A CT60G>A polymorphism in the CTLA-4 gene of the recipient may confer susceptibility to acute graft versus host disease after allogeneic hematopoietic stem cell transplantation.
Karabon L; Markiewicz M; Partyka A; Pawlak-Adamska E; Tomkiewicz A; Dzierzak-Mietla M; Kyrcz-Krzemien S; Frydecka I
Immunogenetics; 2015 Jun; 67(5-6):295-304. PubMed ID: 25940108
[TBL] [Abstract][Full Text] [Related]
14. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.
Allen JL; Fore MS; Wooten J; Roehrs PA; Bhuiya NS; Hoffert T; Sharf A; Deal AM; Armistead P; Coghill J; Gabriel DA; Irons R; Essenmacher A; Shea TC; Richards K; Cutler C; Ritz J; Serody J; Baldwin AS; Sarantopoulos S
Blood; 2012 Sep; 120(12):2529-36. PubMed ID: 22896003
[TBL] [Abstract][Full Text] [Related]
15. Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation.
Partanen J; Hyvärinen K; Bickeböller H; Bogunia-Kubik K; Crossland RE; Ivanova M; Perutelli F; Dressel R
Front Immunol; 2020; 11():575492. PubMed ID: 33193367
[TBL] [Abstract][Full Text] [Related]
16. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.
Sarantopoulos S; Stevenson KE; Kim HT; Bhuiya NS; Cutler CS; Soiffer RJ; Antin JH; Ritz J
Clin Cancer Res; 2007 Oct; 13(20):6107-14. PubMed ID: 17947475
[TBL] [Abstract][Full Text] [Related]
17. Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.
Martin PJ; Fan W; Storer BE; Levine DM; Zhao LP; Warren EH; Flowers ME; Lee SJ; Carpenter PA; Boeckh M; Hingorani S; Yan L; Hu Q; Preus L; Liu S; Spellman S; Zhu X; Pasquini M; McCarthy P; Stram D; Sheng X; Pooler L; Haiman CA; Sucheston-Campbell L; Hahn T; Hansen JA
Blood; 2016 Nov; 128(20):2450-2456. PubMed ID: 27758874
[TBL] [Abstract][Full Text] [Related]
18. Polymorphism of interleukin-23 receptor gene but not of NOD2/CARD15 is associated with graft-versus-host disease after hematopoietic stem cell transplantation in children.
Gruhn B; Intek J; Pfaffendorf N; Zell R; Corbacioglu S; Zintl F; Beck JF; Debatin KM; Steinbach D
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1571-7. PubMed ID: 19896081
[TBL] [Abstract][Full Text] [Related]
19. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
Viel DO; Tsuneto LT; Sossai CR; Lieber SR; Marques SB; Vigorito AC; Aranha FJ; de Brito Eid KA; Oliveira GB; Miranda EC; de Souza CA; Visentainer JE
Scand J Immunol; 2007 Dec; 66(6):703-10. PubMed ID: 18021367
[TBL] [Abstract][Full Text] [Related]
20. Effect of donor CTLA-4 alleles and haplotypes on graft-versus-host disease occurrence in Tunisian patients receiving a human leukocyte antigen-identical sibling hematopoietic stem cell transplant.
Sellami MH; Bani M; Torjemane L; Kaabi H; Ladeb S; Ben Othmane T; Hmida S
Hum Immunol; 2011 Feb; 72(2):139-43. PubMed ID: 21081144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
